Jeffrey C. Goh

Queensland University of Technology — Australia

Medicine · Health Sciences

28h-index9.8kcitations129works15.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(40), Prostate Cancer Treatment and Research(36), Renal cell carcinoma treatment(33), PARP inhibition in cancer therapy(30), Ovarian cancer diagnosis and treatment(22)

Publications124 total

EXERCISE THERAPY ADDED TO FIRST-LINE CHEMOTHERAPY FOR OVARIAN CANCER: EFFECTS ON PROGRESSION-FREE SURVIVAL AND PHYSICAL WELLBEING IN THE RANDOMISED, PHASE 3 ECHO TRIAL (ANZGOG1304/CTC121)
International Journal of Gynecological Cancer·2025
PEMBROLIZUMAB VS PLACEBO PLUS PACLITAXEL ± BEVACIZUMAB FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: RESULTS FROM THE PHASE 3 ENGOT-OV65/KEYNOTE-B96 STUDY
International Journal of Gynecological Cancer·2025
Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066)
Molecular Cancer Therapeutics·2025
Validation and potential refinement of the Malaysia Medication Adherence Assessment Tool (MyMAAT) among patients with non-dialysis chronic kidney disease
PLoS ONE·2025Open Access
1222TiP TroFuse-022/ENGOT-ov84/GOG-3103 part 1: A phase III study of sacituzumab tirumotecan (Sac-TMT) ± bevacizumab (Bev) maintenance therapy vs standard of care (SoC) after second-line (2L) platinum-based doublet chemotherapy (chemo) for platinum-sensitive recurrent ovarian cancer (PSROC)
Annals of Oncology·2025
2388P Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trial
Annals of Oncology·2025
CN88 A phase II randomized trial of nurse led telehealth follow-up including patient reported outcomes using the MOST-S26 (measure of ovarian symptoms and treatment concerns) versus routine clinic based or telehealth follow-up, after completion of chemotherapy in patients with ovarian cancer
Annals of Oncology·2025
2394P Circulating tumour cell (CTC) characteristics associated with survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) in a randomised trial of enzalutamide with or without [177Lu]Lu-PSMA-617 (ENZA-p; ANZUP 1901)
Annals of Oncology·2025
Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G
European Urology Focus·2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
The Lancet Oncology·2025· 12 cited
Enhancing treatment outcomes after gynaecological cancer (ACUMEN): a randomised controlled exercise trial protocol
BMC Cancer·2025Open Access
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer
European Urology Oncology·2025· 2 citedOpen Access
Administration of nivolumab plus ipilimumab: Infusion of the fixed‐ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)
Cancer·2025Open Access
How to Support Participants in Urogenital and Prostate Clinical Trials: A Qualitative Perspective
Psycho-Oncology·2025Open Access
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial
European Journal of Cancer·2025· 4 citedOpen Access
Erratum to ‘Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma’ [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644]
International Journal of Gynecological Cancer·2025Open Access
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
Annals of Oncology·2025· 3 citedOpen Access
Association of early PSMA upregulation with duration of response to enzalutamide with or without [177Lu]Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: Findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901)
2025Open Access
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
The Lancet Oncology·2025· 39 cited
Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201).
Journal of Clinical Oncology·2025
page 1 of 7Next →

Frequent Co-authors

Robert J. Motzer(15), Peter C.C. Fong(12), Viktor Grünwald(11), Nicoletta Colombo(11), Andrew R. Clamp(11), Camillo Porta(10), Toni K. Choueiri(10), Amit M. Oza(10), Domenica Lorusso(10), Carol Aghajanian(10), Ana Oaknin(10), Andrew Dean(10), Johanne I. Weberpals(10), Giovanni Scambia(10), Alexandra Léary(10), Margarita Amenedo(10), David A. Pattison(10), Robert L. Coleman(9), David M. O’Malley(9), Sandra Goble(9)